The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Preliminary findings from the QOL-ONE PHOENIX study of luspatercept in del(5q) MDS
Esther Oliva, MD, London North West University Healthcare NHS Trust, London, UK, discusses the QOL-ONE PHOENIX study, evaluating luspatercept in patients with del(5q) myelodysplastic syndromes (MDS) who are refractory or intolerant to prior treatments. Dr Oliva highlights preliminary findings indicating that this agent has efficacy in this patient population. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is a single arm study and it’s a small, we can almost say pilot study, in a small number of patients. The trial is still finalizing so all patients have been recruited. What we can say is that there is efficacy in terms of at least, we could say now from the preliminary results, up to a 50% response rate with luspatercept in a particularly difficult group of patients who are normally excluded from clinical trials have either previously failed erythropoietin or did not have an indication for erythropoietin and would otherwise not receive any other treatment...
So this is a single arm study and it’s a small, we can almost say pilot study, in a small number of patients. The trial is still finalizing so all patients have been recruited. What we can say is that there is efficacy in terms of at least, we could say now from the preliminary results, up to a 50% response rate with luspatercept in a particularly difficult group of patients who are normally excluded from clinical trials have either previously failed erythropoietin or did not have an indication for erythropoietin and would otherwise not receive any other treatment. Obviously these are patients that were supposed to be receiving lenalidomide, either failed, were intolerant, or for some reason did not have an indication. For these patients, we have an alternative, which is luspatercept, which I definitely, even though the results are preliminary, I can definitely say that it has efficacy. So we’re happy to probably finalize the study in a couple of months and report final results.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
